Retatrutide

Retatrutide is an experimental unimolecular incretin/glucagon receptor agonist engineered to co-activate GLP-1, GIP, and glucagon signaling pathways. Preclinical and clinical research has focused on its potential to produce substantial weight loss and metabolic improvements through combined central and peripheral effects on food intake, glucose homeostasis, and energy expenditure.